Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small mole...
Q2 2026
Jan 30, 2026
FY 2025
Aug 29, 2025
Q4 2025
Q2 2025
Feb 28, 2025
Q1 2025
Sep 30, 2024
